Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.

Nguyen T, Gamage TF, Decker AM, Barrus D, Langston TL, Li JX, Thomas BF, Zhang Y.

J Med Chem. 2019 Nov 14;62(21):9806-9823. doi: 10.1021/acs.jmedchem.9b01161. Epub 2019 Oct 24.

PMID:
31596583
2.

Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

PMID:
30705707
3.

Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.

Gamage TF, Farquhar CE, McKinnie RJ, Kevin RC, McGregor IS, Trudell ML, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2019 Mar;368(3):414-422. doi: 10.1124/jpet.118.254425. Epub 2018 Dec 14.

PMID:
30552295
4.

Sex, THC, and hormones: Effects on density and sensitivity of CB1 cannabinoid receptors in rats.

Farquhar CE, Breivogel CS, Gamage TF, Gay EA, Thomas BF, Craft RM, Wiley JL.

Drug Alcohol Depend. 2019 Jan 1;194:20-27. doi: 10.1016/j.drugalcdep.2018.09.018. Epub 2018 Oct 25.

PMID:
30391834
5.

Diarylureas Containing 5-Membered Heterocycles as CB1 Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation.

Nguyen T, Gamage TF, Decker AM, German N, Langston TL, Farquhar CE, Kenakin TP, Wiley JL, Thomas BF, Zhang Y.

ACS Chem Neurosci. 2019 Jan 16;10(1):518-527. doi: 10.1021/acschemneuro.8b00396. Epub 2018 Sep 20.

PMID:
30188693
6.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

7.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

8.

The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL.

Neuropharmacology. 2017 Oct;125:365-375. doi: 10.1016/j.neuropharm.2017.08.008. Epub 2017 Aug 10.

9.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.

Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2017 Sep 14;60(17):7410-7424. doi: 10.1021/acs.jmedchem.7b00707. Epub 2017 Aug 18.

10.

CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.

Gamage TF, Anderson JC, Abood ME.

Cannabis Cannabinoid Res. 2016 Dec;1(1):272-280. doi: 10.1089/can.2016.0028.

11.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

12.

Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

Meza-Aviña ME, Lingerfelt MA, Console-Bram LM, Gamage TF, Sharir H, Gettys KE, Hurst DP, Kotsikorou E, Shore DM, Caron MG, Rao N, Barak LS, Abood ME, Reggio PH, Croatt MP.

Bioorg Med Chem Lett. 2016 Apr 1;26(7):1827-1830. doi: 10.1016/j.bmcl.2016.02.030. Epub 2016 Feb 16.

13.

Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.

Gamage TF, Ignatowska-Jankowska BM, Muldoon PP, Cravatt BF, Damaj MI, Lichtman AH.

Drug Alcohol Depend. 2015 Jan 1;146:7-16. doi: 10.1016/j.drugalcdep.2014.11.015. Epub 2014 Nov 26.

14.

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.

Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA, Pertwee RG, Lichtman AH.

Behav Pharmacol. 2014 Apr;25(2):182-5. doi: 10.1097/FBP.0000000000000027.

15.

Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.

Ramesh D, Gamage TF, Vanuytsel T, Owens RA, Abdullah RA, Niphakis MJ, Shea-Donohue T, Cravatt BF, Lichtman AH.

Neuropsychopharmacology. 2013 May;38(6):1039-49. doi: 10.1038/npp.2012.269. Epub 2013 Jan 3.

16.

l-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in mice.

Wise LE, Premaratne ID, Gamage TF, Lichtman AH, Hughes LD, Harris LS, Aceto MD.

Pharmacol Biochem Behav. 2012 Dec;103(2):245-52. doi: 10.1016/j.pbb.2012.08.008. Epub 2012 Aug 23.

17.

The endocannabinoid system: role in energy regulation.

Gamage TF, Lichtman AH.

Pediatr Blood Cancer. 2012 Jan;58(1):144-8. doi: 10.1002/pbc.23367. Review.

18.

Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride.

Vann RE, Walentiny DM, Burston JJ, Tobey KM, Gamage TF, Wiley JL.

Neuropharmacology. 2012 Feb;62(2):1019-27. doi: 10.1016/j.neuropharm.2011.10.011. Epub 2011 Oct 31.

19.

The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice.

Walentiny DM, Gamage TF, Warner JA, Nguyen TK, Grainger DB, Wiley JL, Vann RE.

Eur J Pharmacol. 2011 Apr 10;656(1-3):63-7. doi: 10.1016/j.ejphar.2011.01.056. Epub 2011 Feb 11.

20.

Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.

Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, Damaj MI.

J Pharmacol Exp Ther. 2010 Jul;334(1):137-46. doi: 10.1124/jpet.110.165738. Epub 2010 Apr 16.

21.

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):191-8. doi: 10.1016/j.drugalcdep.2007.11.017.

22.

Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats.

Wright MJ Jr, Vann RE, Gamage TF, Damaj MI, Wiley JL.

Pharmacol Biochem Behav. 2006 Nov;85(3):507-13. Epub 2006 Nov 16.

Supplemental Content

Loading ...
Support Center